Journal Article Review Epublish
PubMed: 40333307 DOI: 10.3390/vaccines13040406
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.
Vaccines (Basel) 13(4)
Authors: Muralimanohara S T Murala, Vivek Gairola, Ekramy E Sayedahmed, Suresh K Mittal
Affiliations
- Department of Comparative Pathobiology, Purdue Institute of Inflammation, Immunology and Infectious Disease, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-2027, USA.
Abstract
This review systematically revises adenovirus (Ad) biology, vector structure, immune responses, and currently available Ad vector COVID-19 vaccines. It analyzes the challenges associated with the Ad vector-based vaccines, including preexisting vector immunity and other side effects. Moreover, this review explores novel and innovative strategies to overcome these constraints for developing next-generation vaccines for broad protection to cover emerging SARS-CoV-2 variants. The future refinement of Ad vaccine platforms will be pivotal in achieving durable immunity against emerging variants for global preparedness.
MeSH
Coronavirus, Sars-Cov-2, Vaccines, Severe Acute Respiratory Syndrome, Immunity